Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

vidofludimus

Known as: 2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid, 4SC-101 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsDicarboxylic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
BACKGROUND Inhibition of dihydroorotate dehydrogenase (DHODH) is an established mechanism for the treatment of relapsing… Expand
  • table 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
2020
2020
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
Background and Objective Vidofludimus is a potent and selective inhibitor of human mitochondrial enzyme dihydroorotate… Expand
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • table 3
2019
2019
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
The dihydroorotate dehydrogenase (DHODH) inhibitors leflunomide and teriflunomide are immunomodulatory agents approved to treat… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2013
2013
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
BACKGROUND Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the… Expand
  • figure 2
2012
2012
Vidofludimus Inhibits Colonic Interleukin-17 and Improves Hapten-Induced Colitis in Rats by a Unique Dual Mode of Action
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Immunosuppression With 4SC-101, a Novel Inhibitor of Dihydroorotate Dehydrogenase, in a Rat Model of Renal Transplantation
Background 4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with… Expand
2011
2011
Inhibition of IL-17 Release by the Novel Anti-Inflammatory Drug Vidofludimus Involves Attenuation of STAT3 and NF-kappa B Signaling Pathways in Murine Splenocytes and Hapten-Induced Colitis
IL-17 Secretion: Murine Splenocytes Vidofludimus Inhibits the Nuclear Binding of STAT3 in a Dose Dependent Fashion: Murine… Expand
Highly Cited
2010
Highly Cited
2010
4SC‐101, a novel immunosuppressive drug, inhibits IL‐17 and attenuates colitis in two murine models of inflammatory bowel disease†
Background: Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… Expand
2010
2010
Immunopathology and Infectious Diseases 4 SC-101 , A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor , Suppresses Systemic Lupus Erythematosus in MRL-( Fas ) lpr Mice
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE